Basel, March 27, 2019 – Novartis today announced that the US Food and Drug Administration (FDA) has approved Mayzent (siponimod) for the treatment of adults with relapsing forms of multiple sclerosis, including secondary progressive multiple…Original Article
FDA Approves Mayzent (siponimod) for Secondary Progressive Multiple Sclerosis
